To evaluate the high tumor accumulation of albumin-binding Al-ProD by extended in vivo half-life, the pharmacokinetics (PK) of Al-ProD and free DOX was firstly compared in BALB/c nude mice after intravenous injection at a dose of molar equivalent to 3 mg/kg of doxorubicin. The gene discussed is ALB; the disease is neoplasm.